68076-37-9

Upstream product

• 34637-22-4 3-[(N-benzyloxycarbonyl)amino]propanol 
• 98-59-9 p-toluenesulfonyl chloride 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 57512-02-4 S-(N-Benzyloxycarbonyl-3-amino-propyl)-homocystein 
• 204061-09-6 7-(N-phenylmethoxycarbonyl)amino-4-azaheptanol 
• 439093-11-5 {3-[(3-dimethylamino-propyl)-methyl-amino]-propyl}-carbamic acid benzyl ester 
• 204061-17-6 {3-[Benzyloxycarbonyl-(3-hydroxy-propyl)-amino]-propyl}-carbamic acid benzyl ester 
• 245119-66-8 {3-[benzyloxycarbonyl-(3-oxo-propyl)-amino]-propyl}-carbamic acid benzyl ester 
• 245119-67-9 [3-(azacyclotridec-1-yl)-propyl]-(3-benzyloxycarbonylamino-propyl)-carbamic acid benzyl ester 
• 245119-68-0 [3-(azacyclotetradec-1-yl)-propyl]-(3-benzyloxycarbonylamino-propyl)-carbamic acid benzyl ester 
• 879484-67-0 phenylmethyl {3-[(1,1-dimethylethyl)amino]propyl}carbamate 

Relevant academic research and scientific papers

Total synthesis of cytotoxic sponge alkaloids motuporamines A and B

The synthesis of two sponge alkaloids, Motuporamines A and B is reported. The key step involved a reductive amination using sodium triacetoxyborohydride.

IMIDE-BASED MODULATORS OF PROTEOLYSIS AND METHODS OF USE

The description relates to imide-based compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.

Polymer-Supported Chiral-at-Metal Lewis Acid Catalysts

The covalent immobilization of a chiral-at-metal bis-cyclometalated iridium(III) catalyst on a solid support is reported, and its catalytic activity has been investigated. As a catalyst immobilization strategy, a catalyst precursor was tethered to polystyrene macrobeads through an ester or amide linkage and subsequently converted to the immobilized active chiral Lewis acid by treatment with a Br?nsted acid. The amide-linked catalyst displays high robustness and can be recycled multiple times without deterioration of enantioselectivity and only a gradual loss of catalytic activity. Chiral Lewis acid activity was demonstrated as an example for the enantioselective Friedel-Crafts alkylation of indole with an α,β-unsaturated 2-acyl imidazole and for the enantioselective Diels-Alder reactions of an α,β-unsaturated 2-acyl imidazole with 2,3-dihydrofuran or isoprene.

2,4-SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS

Substituted heteroaryl nitrile derivatives of Formula (I) processes for their preparation, pharmaceutical compositions comprising such compounds and use of the compounds as cysteine protease inhibitors are provided.

Nonpeptide bradykinin B2 receptor antagonists: Conversion of rodent-selective bradyzide analogues into potent, orally-active human bradykinin B2 receptor antagonists

The 1-(2-nitrophenyl)thiosemicarbazide (TSC) derivative, (S)-l-[4-(4-benzhydrylthiosemicarbazido)-3-nitrobenzenesulfonyl] pyrrolidine-2-carboxylic acid {2-[(2-dimethylaminoethyl)methylamino]ethyl} amide (bradyzide; (S)-4), was recently disclosed as a novel, potent, orally active nonpeptide bradykinin (BK) B2 receptor antagonist. The compound inhibited the specific binding of [3H]BK to NG108-15 cell membrane preparations (rodent neuroblastoma-glioma) expressing B2 receptors with a Ki of 0.5 ± 0.2 nM. Compound (S)-4 also demonstrated oral efficacy against Freund's complete adjuvant (FCA)-induced mechanical hyperalgesia in rats with an ED50 value of 0.84 μmol/kg. After we optimized the terminal binding determinants projecting from the TSC framework, we found that it was possible to replace the potentially toxicophoric nitro and divalent sulfur moieties with only a 15-fold loss in binding affinity ((S)-14a). However, bradyzide and its congeners were found to have much lower affinities for cloned human B2 receptors, expressed in Cos-7 cells. The hitherto synthesized TSC series was screened against the human B2 receptor, and the dibenzosuberane (DBS) pharmacophore emerged as the key structural requirement for potency. Incorporation of this group resulted in a series of derivatives ((S)-14d,e and 19b-d) with Ki ranges of 10.7-176 nM in NG108-15 cells (expressing the rodent B2 receptor) and 0.79-253 nM in Cos-7 cells (expressing the human B2 receptor). There was no evidence of agonist activity with any of the nonpeptides in any of the cell lines tested. In vivo, oral administration of compound 19c reversed FCA-induced and turpentine-induced mechanical hyperalgesia in rodents with ED50 values of 0.027 and 0.32 μmol/kg, respectively. The selectivity profiles of compounds (S)-14f and (S)-14g were also assessed to determine the conformational and/or steric preferences of the double-ring arrangement. The affinity of (S)-14g for the human B2 receptor suggested that it may be a hydrophobic interaction with the ethane bridge of the DBS moiety that accounts for the increased potency of compounds (S)-14d,e and 19b,c at this receptor, by favoring a binding mode inaccessible to the unsubstituted diphenylmethyl derivative, (S)-4.

42. Reinigung der D-Oxynitrilase aus Mandeln mit Hilfe der Affinitaets-Chromatographie

Oxynitrilase from almond meal is capable of catalysing the stereospecific addition of cyanide to a variety of aldehydes.Thus, the enzyme is potentially useful in the synthesis of optically active cyanohydrins on a preparative scale .As the currently av